Literature DB >> 28803887

A miniaturized peptidyl-prolyl isomerase enzyme assay.

Mirella Vivoli1, Julien Renou2, Arnaud Chevalier2, Isobel H Norville3, Suraya Diaz1, Christina Juli4, Helen Atkins3, Ulrike Holzgrabe4, Pierre-Yves Renard2, Mitali Sarkar-Tyson5, Nicholas J Harmer6.   

Abstract

Prolyl-peptidyl isomerases (PPIases) are enzymes that are found in all living organisms. They form an essential part of the cellular protein folding homeostasis machinery. PPIases are associated with many important human diseases, e.g. cardiovascular disease, cancer and Alzheimer's. The development of novel PPIase inhibitors has been limited by the lack of a rapid, laboratory-based assay for these enzymes, as their substrates and products are challenging to distinguish. A well described continuous assay, coupled with the hydrolysis of a peptide by chymotrypsin is highly effective, but comparatively slow. To address this, we developed an improved version of the traditional assay using a temperature controlled plate reader. This assay allows semi-automated medium throughput assays in an academic laboratory for 84 samples per day. The assay shows lower errors, with an average Z' of 0.72. We further developed the assay using a fluorogenic peptide-based FRET probe. This provides an extremely sensitive PPIase assay using substrate at 200 nM, which approaches single turnover conditions. The fluorescent probe achieves an excellent quenching efficiency of 98.6%, and initial experiments showed acceptable Z' of 0.31 and 0.30 for cyclophilin A and hFKBP12 respectively. The assays provide an improved toolset for the quantitative, biochemical analysis of PPIases. Crown
Copyright © 2017. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assay development; Cyclophilin; FKBP12; Fluorescence; High throughput; Inhibitor; Peptide

Mesh:

Substances:

Year:  2017        PMID: 28803887     DOI: 10.1016/j.ab.2017.08.004

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  1 in total

1.  Broad-spectrum in vitro activity of macrophage infectivity potentiator inhibitors against Gram-negative bacteria and Leishmania major.

Authors:  Jua Iwasaki; Donald D Lorimer; Mirella Vivoli-Vega; Emily A Kibble; Christopher S Peacock; Jan Abendroth; Stephen J Mayclin; David M Dranow; Phillip G Pierce; David Fox; Maria Lewis; Nicole M Bzdyl; Sofie S Kristensen; Timothy J J Inglis; Charlene M Kahler; Charles S Bond; Anja Hasenkopf; Florian Seufert; Jens Schmitz; Laura E Marshall; Andrew E Scott; Isobel H Norville; Peter J Myler; Ulrike Holzgrabe; Nicholas J Harmer; Mitali Sarkar-Tyson
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.